Search alternatives:
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
-
401
-
402
-
403
-
404
Image 2_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff
Published 2024“…The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC.</p>Results and discussion<p>Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. …”
-
405
Table 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.xlsx
Published 2024“…The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC.</p>Results and discussion<p>Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. …”
-
406
Image 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff
Published 2024“…The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC.</p>Results and discussion<p>Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. …”
-
407
Data_Sheet_1_Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.docx
Published 2022“…In this scenario of high SARS-CoV-2 circulation, we analyzed the effectiveness of the country's vaccination strategy that used 7 different vaccines from around the world, and focused on vaccinating the oldest population first. …”
-
408
-
409
Image_5_Catheter-Based Therapies Decrease Mortality in Patients With Intermediate and High-Risk Pulmonary Embolism: Evidence From Meta-Analysis of 65,589 Patients.TIF
Published 2022“…Background<p>Catheter-directed therapies (CDT) are an alternative to systemic thrombolysis (ST) in pulmonary embolism (PE) patients, but the mortality benefit of CDT is unclear.</p>Objective<p>We conducted a systematic review with meta-analysis to compare the efficacy and safety of CDT and ST in intermediate-high and high-risk PE.…”
-
410
-
411
-
412
-
413
-
414
Table_1_Soil Properties Interacting With Microbial Metagenome in Decreasing CH4 Emission From Seasonally Flooded Marshland Following Different Stages of Afforestation.xlsx
Published 2022“…Compared to the non-afforested land use types, net CH<sub>4</sub> emission decreased from bare land, natural vegetation and 5-year forest plantation and transitioned to net CH<sub>4</sub> sinks in the 10- and 20-year forest plantations. …”
-
415
Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression.
Published 2019“…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
-
416
-
417
-
418
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
419
-
420